KRAS and neoplasm: Instead, our work provided an alternative solution, altering the phenotypic state of mitochondria driven by KRAS through Drp1, which in turn suppresses tumor growth through modulating levels of defective mitochondria and limiting OXPHOS capability in PDAC [3].